Hepatera Ltd. announces initiation of a clinical trial investigating Myrcludex B in chronically HBV infected patients who are also infected with hepatitis delta virus (HDV). Hepatera is financed by Maxwell Biotech Venture Fund formed with the participation...
Co-Invests with Germany’s Public/Private High-Tech Gründerfonds, one of Europe’s Top Venture Funds Maxwell Biotech Venture Fund (MBVF), founded with the participation of the Russian Government’s Russian Venture Company, announced today...
Today, April 4th, Maxwell Biotech Venture Fund (MBVF), founded with the participation of RVC, and High-Tech Gründerfonds (HTGF), one of Europe’s largest venture funds, signed a Letter of Intent between the two funds during a joint press conference...
Hepatera, a Russian biotech company founded in late 2011 with the goal to develop and launch into the Russian market innovative products for treatment of liver diseases, has recently received notification from the Russian Ministry of Health for approval to...
Hepatera, a Russian biotech company and part of Maxwell Biotech Venture Fund's portfolio, has announced today the inclusion of the first three patients with chronic hepatitis B in the clinical trial phase Ib-IIa of Myrcludex B. Hepatera was founded in 2011...
A biotechnology company "Hepatera" organized phase Ib-IIa clinical study of Myrcludex B in specialized clinical centers in Moscow, St. Petersburg, Chelyabinsk and Samara. According to the PR office of the company, the developed drug is a synthesized...